---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-041708"
form_type: "8-K"
ticker: null
cik: "0001845459"
company_name: "NKGen Biotech, Inc."
filed_at: "2024-05-10T23:59:59+00:00"
generated_at: "2026-06-02T04:09:39.019607+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# NKGen Biotech raises $1M gross from convertible notes; warrants at $2.00

## Summary
- Total gross proceeds of $1M from three convertible promissory notes to Meteora ($200k), Alpha ($500k), and AJB ($300k).
- Aggregate principal amount $1.21M; notes mature in 12 months; convertible at $2.00 per share.
- Warrants issued to purchase up to 1.1M shares at $2.00 per share for five years.
- Alpha and AJB have options to require additional notes and warrants worth up to $2.96M and 2.64M shares.
- Notes include original issue discounts; Meteora Note bears 12% interest; others zero coupon.

## SEC filing metadata
- accession: 0001213900-24-041708
- form_type: 8-K
- cik: 0001845459
- company_name: NKGen Biotech, Inc.
- filed_at: 2024-05-10T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1845459/000121390024041708/0001213900-24-041708-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1845459/000121390024041708/ea0205751-8k_nkgenbio.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-041708
- JSON: https://secwatch.observer/filing/0001213900-24-041708.json
- Plain text: https://secwatch.observer/filing/0001213900-24-041708.txt

## Key facts
- Material Agreements
  NKGen Biotech, Inc. entered into Meteora Purchase Agreement with Meteora Select Trading Opportunities Master, LP, Meteora Capital Partners, LP and Meteora Strategic Captial, LLC (collectively, "Meteora") valued at $220,000 (effective 2024-05-07).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Meteora Select Trading Opportunities Master, LP, Meteora Capital Partners, LP and Meteora Strategic Captial, LLC (collectively, "Meteora")
  - Value: $220,000
  - Effective: 2024-05-07
  source text: On May 7, 2024, the Company issued a 12% promissory note (the “ Meteora Note ”) in the principal amount of $220,000, pursuant to a Securities Purchase Agreement (the “ Meteora Purchase Agreement ”), by and among Meteora Select Trading Opportunities Master, LP, Meteora Capital Partners, LP and Meteora Strategic Captial, LLC (collectively, “ Meteora ”) and the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1845459/000121390024041708/0001213900-24-041708-index.htm
- Material Agreements
  NKGen Biotech, Inc. entered into AJB Purchase Agreement with AJB Capital Investments LLC ("AJB") valued at $369,600 (effective 2024-05-09).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: AJB Capital Investments LLC ("AJB")
  - Value: $369,600
  - Effective: 2024-05-09
  source text: On May 9, 2024, the Company entered into to a Securities Purchase Agreement (the “ AJB Purchase Agreement ”), by and between AJB Capital Investments LLC (“ AJB ”) and the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1845459/000121390024041708/0001213900-24-041708-index.htm
- Material Agreements
  NKGen Biotech, Inc. entered into Alpha Purchase Agreement with Generating Apha Ltd. ("Alpha") valued at $616,000 (effective 2024-05-07).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Generating Apha Ltd. ("Alpha")
  - Value: $616,000
  - Effective: 2024-05-07
  source text: On May 7, 2024, the Company issued a zero coupon promissory note (the “ Alpha Note ”) in the principal amount of $616,000, pursuant to a Securities Purchase Agreement (the “ Alpha Purchase Agreement ”), by and between Generating Apha Ltd. (“ Alpha ”) and the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1845459/000121390024041708/0001213900-24-041708-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.